Understanding Peptide Purity Testing: What a Janoshik Report Actually Tells You

AI generatedEducationTesting
This article was AI-generated for informational purposes only. It is not medical advice. Always verify claims with the cited sources.

For anyone sourcing research peptides outside of pharmaceutical supply chains, third-party analytical testing is the single most important quality assurance tool available. Among independent testing services, Janoshik Analytical has become one of the most widely referenced labs in the peptide research community. But receiving a certificate of analysis (COA) is only useful if you understand what the numbers actually mean.

This guide breaks down the key components of a typical peptide purity report, explains the analytical methods behind them, and highlights what the results can — and cannot — tell you about the compound in your hands.

Why Third-Party Testing Matters

Peptide vendors typically provide their own COAs, but these documents carry an inherent conflict of interest. The supplier is simultaneously the manufacturer and the entity certifying quality. Research has consistently shown that self-reported purity claims in the unregulated peptide market are unreliable.

A study by Venhuis et al., 2014 analyzing peptides sold online found that a significant proportion of products were mislabeled, underdosed, or contained unexpected impurities. More recently, Spink et al., 2019 described how economically motivated adulteration affects a wide range of consumer products, including research chemicals.

Third-party testing from an independent lab removes this conflict. Janoshik Analytical, based in the Czech Republic, has become a go-to resource because it operates independently of any peptide vendor, provides standardized reports, and uses validated analytical methods that are well-understood in the pharmaceutical sciences.

HPLC Purity: The Headline Number

The most prominent figure on any Janoshik peptide report is HPLC purity, expressed as a percentage. HPLC stands for High-Performance Liquid Chromatography, and it is the gold-standard technique for assessing peptide purity in both research and pharmaceutical contexts.

HPLC works by dissolving the sample in a solvent and pushing it through a column packed with stationary phase material. Different molecules travel through the column at different rates based on their physicochemical properties. A UV detector at the end of the column records peaks corresponding to each separated component. The purity percentage is calculated by comparing the area of the main peptide peak to the total area of all detected peaks.

A result of ≥98% HPLC purity is generally considered research-grade quality. Most pharmaceutical-grade peptides target ≥99%. A purity of 95% means that roughly 5% of the sample by chromatographic area consists of impurities — which could include truncated sequences, deletion peptides, oxidized forms, or residual synthesis byproducts.

It is important to understand what HPLC purity does not tell you. As explained in foundational analytical chemistry literature (Snyder et al., 2010), HPLC measures relative proportions of detectable components in a sample. It does not directly confirm molecular identity, and it may not detect impurities that co-elute with the main peak or that lack UV absorbance.

Mass Spectrometry: Confirming Identity

While HPLC tells you how pure a sample is, mass spectrometry (MS) tells you what the sample actually is. Janoshik reports typically include MS data showing the observed molecular weight of the primary compound compared to the theoretical molecular weight of the target peptide.

Mass spectrometry ionizes the sample molecules and measures their mass-to-charge ratio (m/z). For peptides, this usually means observing the [M+H]⁺ ion (the protonated molecular ion) or multiply charged species like [M+2H]²⁺ for larger sequences. If the observed mass matches the expected mass within instrument tolerance — typically ±0.1–0.5 Da for standard instruments — this confirms that the correct peptide is present.

According to Dass, 2007, mass spectrometry is considered the definitive technique for peptide identification. Without MS data, a high HPLC purity number is essentially meaningless — you could have a very pure sample of the wrong compound.

Amino Acid Content and Peptide Content

Some reports include a figure called peptide content, which is distinct from purity and often misunderstood. Peptide content refers to the mass fraction of the lyophilized powder that is actual peptide, as opposed to residual water, salts (like acetate or TFA from synthesis), and other non-peptide components.

A typical peptide content value falls between 60–80% even for high-purity peptides. This does not mean the peptide is impure — it means that the remaining mass consists of counter-ions and moisture that are normal byproducts of solid-phase peptide synthesis and lyophilization.

Coin et al., 2007 describe in their Nature Protocols paper on peptide synthesis how counter-ions from cleavage and purification steps are inherently present in synthetic peptides. Researchers calculating doses based on gross powder weight without accounting for peptide content may introduce 20–40% dosing errors, which is a significant consideration in quantitative research.

Understanding Impurity Profiles

Beyond the headline purity number, the impurity profile revealed by HPLC chromatography provides valuable information. Most Janoshik reports include the chromatogram itself, showing:

  • The main peak — representing the target peptide
  • Minor peaks — representing impurities, each reported as a percentage of total area
  • Retention times — indicating the elution behavior of each component
  • Common impurities in synthetic peptides include:

  • Deletion peptides — sequences missing one or more amino acids from failed coupling steps
  • Oxidized species — particularly common in methionine- and tryptophan-containing peptides
  • Diastereomers — resulting from racemization during synthesis
  • Truncated sequences — fragments from incomplete chain assembly
  • TFA/acetate salts — counter-ions from purification
  • D'Hondt et al., 2014 published a comprehensive review of peptide degradation and impurity pathways, noting that oxidation and deamidation are the most frequently observed chemical degradation routes in stored peptides. An impurity profile that shows growing oxidation peaks over time may indicate poor storage conditions rather than initial synthesis failure.

    Endotoxin and Sterility Testing

    Some advanced reports may include bacterial endotoxin testing (BET), typically performed via the Limulus Amebocyte Lysate (LAL) assay. Endotoxins are lipopolysaccharide fragments from gram-negative bacteria that can provoke severe immune responses. The FDA's guidance on endotoxin limits establishes threshold values for injectable pharmaceutical products.

    While standard Janoshik peptide reports focus on identity and purity via HPLC/MS, endotoxin testing represents an additional layer of quality assessment. According to Williams, 2007, the LAL assay remains the most sensitive and widely validated method for detecting bacterial endotoxins, with detection limits in the 0.01–0.1 EU/mL range.

    Limitations of Any Single Lab Report

    No analytical report is infallible. Important limitations to keep in mind include:

  • A COA reflects one sample at one point in time — it does not guarantee batch-to-batch consistency
  • HPLC conditions vary — different column types, gradients, and mobile phases can yield different purity values for the same sample
  • Degradation occurs post-testing — improper storage (exposure to heat, moisture, or light) can reduce purity after the report is issued
  • Not all impurities are detectable — residual solvents, heavy metals, and microbiological contamination require separate specialized assays
  • Verbeke et al., 2023 emphasized in a review of peptide quality control that a comprehensive quality assessment requires multiple orthogonal analytical techniques, not reliance on any single method.

    How to Read the Report Critically

    When reviewing a Janoshik report — or any third-party COA — consider these questions:

  • Does the MS-confirmed mass match the target peptide's theoretical molecular weight?
  • Is HPLC purity ≥98% with no single impurity exceeding 1–2%?
  • Is the peptide content reported, and have you factored it into dose calculations?
  • Does the chromatogram show a clean baseline with a dominant single peak?
  • Was the sample ID clearly linked to a specific batch or order?
  • Key Takeaways

  • HPLC purity measures relative composition but does not confirm identity — always check that mass spectrometry data is included and matches the expected molecular weight.
  • Peptide content (60–80%) is normal and distinct from purity — failing to account for it introduces significant dosing errors in research.
  • Impurity profiles matter more than a single number — examine the chromatogram for oxidation products, deletion peptides, and unexpected peaks.
  • Third-party testing removes vendor conflicts of interest, but a single report reflects one sample at one moment; storage conditions and batch variability still matter.
  • No single analytical method captures everything — HPLC/MS addresses identity and purity, but endotoxin, sterility, and residual solvent testing require separate assays for a complete quality picture.
  • Not medical advice. For research purposes only. Consult a licensed physician before beginning any protocol.